5 alpha-reductase inhibitors monitoring and prostate cancer risk

• 5 alpha-reductase inhibitors (5-ARIs), including finasteride and dutasteride, cause a reduction in serum prostate-specific antigen (PSA) levels by approximately 50% or more after 6 months of continuous therapy (1, 2, 7)
• NHS Specialist Pharmacy Service (SPS) guidance mandates specific baseline, 6-month, and ongoing monitoring protocols for patients receiving 5-ARI therapy (7)

Baseline and Routine Monitoring Protocols

• baseline requirements: perform a baseline digital rectal examination (DRE) and measure baseline serum PSA prior to initiating 5-ARI treatment (7)
• 6-month post-initiation review: re-measure serum PSA at 6 months of treatment; this 6-month value forms the patient's new baseline (7)
• ongoing surveillance: perform periodic DREs and PSA measurements once stable (7)

Interpretation of PSA Values and Abnormal Results

• doubling rule for normal ranges: to compare a measured PSA value on 5-ARI therapy with normal reference ranges for untreated men, the measured value must be doubled (7)
• evaluating PSA rises: any confirmed rise in PSA from the nadir (lowest level reached on treatment) may indicate prostate cancer or non-adherence, requiring clinical evaluation even if the doubled value remains within standard normal limits (1, 4, 7)
• enhanced PSA sensitivity and detection bias: 5-ARI treatment increases the sensitivity of PSA testing for detecting overall and high-grade prostate cancer by suppressing benign tissue volume (PCPT data); benign conditions show the greatest PSA reduction, making persistent elevations more indicative of malignancy (4)

Prostate Cancer Efficacy and Mortality Data

• overall incidence: randomized trials and meta-analyses demonstrate that finasteride significantly reduces overall prostate cancer incidence by 24.8% to 30% (OR 0.70) (3, 4, 5)
• high-grade cancer detection: an absolute increase in detected high-grade prostate cancers (Gleason 7 to 10) was observed in trial arms (OR 2.10), largely attributed to enhanced PSA diagnostic sensitivity and detection bias rather than true carcinogenic induction (3, 4, 5)
• overall prostate cancer mortality: large population-based cohort studies and meta-analyses (over 3.1 million nonusers and 138,000 5-ARI users) show no association between 5-ARI use and increased prostate cancer mortality (aHR 1.04), with longer treatment duration showing a time-dependent reduction in mortality risk (6)

Safety and MHRA Drug Safety Updates

• patient counseling: MHRA Drug Safety Updates advise informing patients to contact a healthcare professional if they experience depression, suicidal ideation/thoughts, or persistent sexual dysfunction while taking 5-ARIs (3, 7)

Reference:

1. Etzioni RD et al. Long-term effects of finasteride on prostate specific antigen levels: results from the Prostate Cancer Prevention Trial. J Urol. 2005;174(3):877-81.
2. Pannek J et al. Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasia. J Urol. 1998;159(2):449-53.
3. Thompson IM et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349(3):215-24.
4. Thompson IM et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98(16):1128-33.
5. Wang L et al. Association of finasteride with prostate cancer - A systematic review and meta-analysis. Medicine (Baltimore). 2020;99(15):e19486.
6. Björnebo L et al. Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality. JAMA Oncol. 2022;8(7):1019-1026.
7. NHS Specialist Pharmacy Service (SPS). 5α-reductase inhibitors (benign prostate hyperplasia) monitoring. NHS SPS Guidance. Published 29 October 2026.